Imiquimod 5% cream as a therapeutic option for extramammary Paget's disease

J Dermatol. 2018 Feb;45(2):216-219. doi: 10.1111/1346-8138.14117. Epub 2017 Nov 8.

Abstract

A wide local excision is the standard treatment for extramammary Paget's disease (EMPD), though this treatment often leads to permanent anogenital mutilation and functional impairment. The purpose of our study is to evaluate the efficacy and safety of the topical application of imiquimod 5% cream for non-invasive EMPD. We examined nine patients with EMPD. Eight of the nine patients were treated with imiquimod 5% cream three times per week for 16 weeks; one case was treated for 6 weeks. The response rate was 100% including five complete remissions. Local irritation was observed in three patients, which was controlled by a provisional withdrawal of the treatment. These results suggest that imiquimod 5% cream may be considered an alternative therapeutic option for the treatment of non-invasive EMPD.

Keywords: in situ; extramammary Paget's disease; imiquimod; skin cancer; topical treatment.

Publication types

  • Clinical Trial

MeSH terms

  • Administration, Cutaneous
  • Aged
  • Aged, 80 and over
  • Aminoquinolines / administration & dosage
  • Aminoquinolines / therapeutic use*
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Female
  • Follow-Up Studies
  • Humans
  • Imiquimod
  • Male
  • Middle Aged
  • Paget Disease, Extramammary / drug therapy*
  • Paget Disease, Extramammary / pathology
  • Prospective Studies
  • Remission Induction / methods
  • Skin / pathology
  • Skin Cream / administration & dosage
  • Skin Cream / therapeutic use
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / pathology
  • Treatment Outcome

Substances

  • Aminoquinolines
  • Antineoplastic Agents
  • Imiquimod